Philip J. Rosenfeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philip J. Rosenfeld has a total of 499 co-authors. Here are the top co-authors by number of shared publications:
Giovanni Gregori
102 shared publicationsYingying Shi
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
34 shared publicationsMengxi Shen
29 shared publicationsQinqin Zhang
Carl Zeiss Meditec, Inc., Dublin, CA, USA
27 shared publicationsOmer Trivizki
26 shared publications- Ruikang K. Wang
University of Washington
26 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 115
From intermediate AMD to geographic atrophy: Biomarkers, endpoints, and a roadmap for next-generation clinical trials
- 29 September 2026
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 115
Open AccessFrom intermediate AMD to geographic atrophy: Biomarkers, endpoints, and a roadmap for next-generation clinical trials
- 11 September 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 292, 538-550
Two-Year Experience With Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Clinical Practice
- 11 September 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 292, 538-550
Two-Year Experience With Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Clinical Practice
- Open Access
- 22 July 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (10) , 101333
Symmetry in the Enlargement Rates of Large Hypertransmission Defects between Eyes in Age-Related Macular Degeneration
- 22 July 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (10) , 101333
Open AccessSymmetry in the Enlargement Rates of Large Hypertransmission Defects between Eyes in Age-Related Macular Degeneration
- 9 July 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 291, 155-163
Comparing Eye-Level and Site-Specific High-Risk Optical Coherence Tomography Biomarkers Preceding the Onset of Large Hypertransmission Defects
- 9 July 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 291, 155-163
Comparing Eye-Level and Site-Specific High-Risk Optical Coherence Tomography Biomarkers Preceding the Onset of Large Hypertransmission Defects
- 9 July 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 291, 19-33
Detection of Hyporeflective Core Drusen and the Onset of Large Choroidal Hypertransmission Defects in Intermediate AMD
- 9 July 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 291, 19-33
Detection of Hyporeflective Core Drusen and the Onset of Large Choroidal Hypertransmission Defects in Intermediate AMD
- Open Access
- 1 July 2026
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 15 (7) , 16
Impact of Swept-Source OCT Angiographic Scanning Speeds on the Detection of Choriocapillaris Flow Deficits in Eyes With AMD.
The impact of swept-source optical coherence tomography angiography (SS-OCTA) scanning speeds (interscan times) on the quantification of choriocapillaris flow deficit percentages (CCFD%) was studied in eyes with nonexudative age-related macular degeneration. We conducted a retrospective review of 30 pairs of scans from 24 age-related macular degeneration subjects enrolled in an ongoing prospective SS-OCTA imaging study. Patients underwent imaging with same day scans at two scanning speeds: 100 kHz and 200 kHz (corresponding with 5.0-ms and 2.5-ms interscan times, respectively). Best practices for CC slab processing and CCFD quantification were implemented, and the compensation level was optimized for each scan. CCFD% measurements were obtained from the 3-mm and 5-mm fovea-centered circles. The mean CCFD% measurements from the 3-mm fovea-centered circles for the 100-kHz and 200-kHz scans were 14.20% and 17.17% respectively, and 10.77% and 12.86% for the 5-mm circles. An agreement analysis showed a significant bias with mean values of 2.96% and 2.09% for the 3-mm and 5-mm circles. The limits of agreement extended predominantly in the positive direction with values of -1.96% to 7.89% and -0.60% to 4.78% in the 3-mm and 5-mm circles, respectively, that emphasize the systematically higher CCFD% recorded using the 200-kHz pattern. No confidence interval for the bias included zero, supporting the significant systematic bias across measurement strategies. SS-OCTA scanning speeds have a significant impact on CCFD% quantification, with slower speeds yielding a lower CCFD%, likely due to the detection of slower CC flow, because of the higher associated interscan times. When following and comparing choriocapillaris flow deficit percentage measurements over time, the same scanning speed should be used at each visit.
- 1 July 2026
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 15 (7) , 16
Open AccessImpact of Swept-Source OCT Angiographic Scanning Speeds on the Detection of Choriocapillaris Flow Deficits in Eyes With AMD.
The impact of swept-source optical coherence tomography angiography (SS-OCTA) scanning speeds (interscan times) on the quantification of choriocapillaris flow deficit percentages (CCFD%) was studied in eyes with nonexudative age-related macular degeneration. We conducted a retrospective review of 30 pairs of scans from 24 age-related macular degeneration subjects enrolled in an ongoing prospective SS-OCTA imaging study. Patients underwent imaging with same day scans at two scanning speeds: 100 kHz and 200 kHz (corresponding with 5.0-ms and 2.5-ms interscan times, respectively). Best practices for CC slab processing and CCFD quantification were implemented, and the compensation level was optimized for each scan. CCFD% measurements were obtained from the 3-mm and 5-mm fovea-centered circles. The mean CCFD% measurements from the 3-mm fovea-centered circles for the 100-kHz and 200-kHz scans were 14.20% and 17.17% respectively, and 10.77% and 12.86% for the 5-mm circles. An agreement analysis showed a significant bias with mean values of 2.96% and 2.09% for the 3-mm and 5-mm circles. The limits of agreement extended predominantly in the positive direction with values of -1.96% to 7.89% and -0.60% to 4.78% in the 3-mm and 5-mm circles, respectively, that emphasize the systematically higher CCFD% recorded using the 200-kHz pattern. No confidence interval for the bias included zero, supporting the significant systematic bias across measurement strategies. SS-OCTA scanning speeds have a significant impact on CCFD% quantification, with slower speeds yielding a lower CCFD%, likely due to the detection of slower CC flow, because of the higher associated interscan times. When following and comparing choriocapillaris flow deficit percentage measurements over time, the same scanning speed should be used at each visit.
- 13 May 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 289, 31-35
Cardiovascular Disease and Age-Related Macular Degeneration
- 13 May 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 289, 31-35
Cardiovascular Disease and Age-Related Macular Degeneration
- Open Access
- 30 March 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (6) , 101179
Novel Clinical Trial Designs for Intermediate Age-Related Macular Degeneration
- 30 March 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (6) , 101179
Open AccessNovel Clinical Trial Designs for Intermediate Age-Related Macular Degeneration
- Open Access
- 3 November 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (14) , 20
Changes in Choriocapillaris Flow Deficits Before and After the Onset of Large Choroidal Hypertransmission Defects in AMD
Eyes with intermediate age-related macular degeneration (iAMD) underwent swept-source optical coherence tomography angiography (SS-OCTA) imaging and were evaluated longitudinally to determine if choriocapillaris flow deficits (CCFDs) developed before or after the formation of large choroidal hypertransmission defects (hyperTDs). A retrospective review was performed of prospectively collected 6 × 6-mm SS-OCTA images from eyes with iAMD that developed large hyperTDs, defined on en face images from subretinal pigment epithelium (sub-RPE) slabs positioned 64 to 400 µm beneath Bruch's membrane (BM) as bright lesions with a greatest linear dimension (GLD) ≥ 250 µm. The onset of large hyperTDs was designated as baseline T = 0; additional visits were chosen at 1 year before and at two 1-year intervals after T = 0. A grid box strategy was implemented for the analysis of CCFDs at the site where hyperTDs formed. A change in the percentage of CCFDs greater than 5% was considered to be a true change outside the repeatability limits. Twenty-seven targets from 27 eyes eligible for final analysis were followed over four visits separated by 12 ± 3 months. No targets showed a marked CCFD change above 5% prior to hyperTD onset. Only two targets showed marked increases in CCFDs after hyperTD formation. A grouped analysis of all targets showed no mean CCFD change prior to hyperTD onset, but a significant change only after the onset of hyperTD. CCFD values did not increase prior to the onset of hyperTDs with increases in CCFDs detected after their onset. These results suggest that loss of choriocapillaris perfusion did not precede hyperTD formation but may play a role in hyperTD growth.
- 3 November 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (14) , 20
Open AccessChanges in Choriocapillaris Flow Deficits Before and After the Onset of Large Choroidal Hypertransmission Defects in AMD
Eyes with intermediate age-related macular degeneration (iAMD) underwent swept-source optical coherence tomography angiography (SS-OCTA) imaging and were evaluated longitudinally to determine if choriocapillaris flow deficits (CCFDs) developed before or after the formation of large choroidal hypertransmission defects (hyperTDs). A retrospective review was performed of prospectively collected 6 × 6-mm SS-OCTA images from eyes with iAMD that developed large hyperTDs, defined on en face images from subretinal pigment epithelium (sub-RPE) slabs positioned 64 to 400 µm beneath Bruch's membrane (BM) as bright lesions with a greatest linear dimension (GLD) ≥ 250 µm. The onset of large hyperTDs was designated as baseline T = 0; additional visits were chosen at 1 year before and at two 1-year intervals after T = 0. A grid box strategy was implemented for the analysis of CCFDs at the site where hyperTDs formed. A change in the percentage of CCFDs greater than 5% was considered to be a true change outside the repeatability limits. Twenty-seven targets from 27 eyes eligible for final analysis were followed over four visits separated by 12 ± 3 months. No targets showed a marked CCFD change above 5% prior to hyperTD onset. Only two targets showed marked increases in CCFDs after hyperTD formation. A grouped analysis of all targets showed no mean CCFD change prior to hyperTD onset, but a significant change only after the onset of hyperTD. CCFD values did not increase prior to the onset of hyperTDs with increases in CCFDs detected after their onset. These results suggest that loss of choriocapillaris perfusion did not precede hyperTD formation but may play a role in hyperTD growth.
- Open Access
- 11 October 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (2) , 100970
Intravitreal Gene Therapy with LX102-C01 in Neovascular Age-Related Macular Degeneration: A Phase I Dose-Escalation Study of 12-Month Safety and Efficacy Outcomes
- 11 October 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (2) , 100970
Open AccessIntravitreal Gene Therapy with LX102-C01 in Neovascular Age-Related Macular Degeneration: A Phase I Dose-Escalation Study of 12-Month Safety and Efficacy Outcomes